AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal.
Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 811.6K | 
| Three Month Average Volume | 12.0M | 
| High Low | |
| Fifty-Two Week High | 22.22 USD | 
| Fifty-Two Week Low | 0.87 USD | 
| Fifty-Two Week High Date | 10 Jan 2024 | 
| Fifty-Two Week Low Date | 09 Aug 2024 | 
| Price and Volume | |
| Current Price | 1.13 USD | 
| Beta | -100,000 | 
| Relative Price Change | |
| Four Week Relative Price Change | -58.54% | 
| Thirteen Week Relative Price Change | -46.94% | 
| Twenty-Six Week Relative Price Change | -65.74% | 
| Fifty-Two Week Relative Price Change | -94.00% | 
| Year-to-Date Relative Price Change | -95.34% | 
| Price Change | |
| One Day Price Change | 0.00% | 
| Thirteen Week Price Change | -43.22% | 
| Twenty-Six Week Price Change | -62.33% | 
| Five Day Price Change | 2.73% | 
| Fifty-Two Week Price Change | -92.49% | 
| Year-to-Date Price Change | -94.49% | 
| Month-to-Date Price Change | -55.69% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.19284 USD | 
| Book Value Per Share (Most Recent Quarter) | 3.29726 USD | 
| Tangible Book Value Per Share (Last Fiscal Year) | 4.19284 USD | 
| Tangible Book Value Per Share (Most Recent Quarter) | 3.29726 USD | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.47473 USD | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD | 
| Revenue Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD | 
| Dividend Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend Per Share (5 Year) | -99999.99 USD | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.74287 USD | 
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.26075 USD | 
| Normalized (Last Fiscal Year) | -2.74287 USD | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.74287 USD | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.26075 USD | 
| Including Extraordinary Items (Last Fiscal Year) | -2.74287 USD | 
| Including Extraordinary Items (Trailing Twelve Months) | -2.26075 USD | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.60759 USD | 
| Cash Per Share (Most Recent Quarter) | 3.50464 USD | 
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD | 
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD | 
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.11568 USD | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 | 
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% | 
| Pretax Margin (Last Fiscal Year) | -99,999.99% | 
| Pretax Margin (5 Year) | -99,999.99% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% | 
| Gross Margin (Trailing Twelve Months) | -99,999.99% | 
| Gross Margin (5 Year) | -99,999.99% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% | 
| Operating Margin (Trailing Twelve Months) | -99,999.99% | 
| Operating Margin (5 Year) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% | 
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% | 
| Net Profit Margin (5 Year) | -99,999.99% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% | 
| Tangible Book Value (5 Year) | -99,999.99% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% | 
| Revenue Growth (3 Year) | -99,999.99% | 
| Revenue Change (Trailing Twelve Months) | -99,999.99% | 
| Revenue Per Share Growth | -99,999.99% | 
| Revenue Growth (5 Year) | -99,999.99% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% | 
| Total Debt (5 Year) | -99,999.99% | 
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 40.29% | 
| EPS Change (Trailing Twelve Months) | 19.19% | 
| EPS Growth (3 Year) | -99,999.99% | 
| EPS Growth (5 Year) | -99,999.99% | 
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% | 
| EBITDA (5 Year Interim) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 | 
| Price to Tangible Book (Most Recent Quarter) | 0 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | -104,540,000 | 
| Net Debt (Last Fiscal Year) | -107,295,000 | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 | 
| Price to Sales (Trailing Twelve Months) | -100,000 | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 | 
| PE Normalized (Last Fiscal Year) | -100,000 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% | 
| Dividend Yield | -99,999.99% | 
| Current Dividend Yield | 0.00% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 | 
| Price to Book (Most Recent Quarter) | 0 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 | 
| Long Term Debt to Equity (Most Recent Quarter) | 0 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% | 
| Payout Ratio (Trailing Twelve Months) | -99,999.99% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 | 
| Quick Ratio (Most Recent Quarter) | -100,000 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 | 
| Current Ratio (Most Recent Quarter) | 11 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -53,288,000 | 
| Free Cash Flow (Trailing Twelve Months) | -60,845,000 | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 | 
| Net Interest Coverage (Trailing Twelve Months) | -100,000 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 | 
| Total Debt to Equity (Most Recent Quarter) | 0 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -53.65% | 
| Return on Assets (Trailing Twelve Months) | -62.35% | 
| Return on Assets (5 Year) | -99,999.99% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -58.83% | 
| Return on Equity (Trailing Twelve Months) | -69.48% | 
| Return on Equity (5 Year) | -99,999.99% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -58.83% | 
| Return on Investment (Trailing Twelve Months) | -69.48% | 
| Return on Investment (5 Year) | -99,999.99% |